Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) — Net Asset Quality Index
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) has a Net Asset Quality Index of -1447.3% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $196.34K minus total liabilities of $3.04 Million yields net assets of $-2.84 Million. A higher index indicates a stronger, lower-leverage balance sheet. See LABT net assets for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Lakewood-Amedex Biotherapeutics Inc. Common Stock Net Asset Quality Index Over Time (2023–2025)
This chart shows how Lakewood-Amedex Biotherapeutics Inc. Common Stock's Net Asset Quality Index has evolved across 3 annual periods from 2023 to 2025. As of March 2026, the index stands at -1447.3%, representing net assets of $-2.84 Million against total assets of $196.34K USD. Explore LABT cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Net Asset Quality Index for Lakewood-Amedex Biotherapeutics Inc. Common Stock (2023–2025)
The table below presents the year-by-year Net Asset Quality Index for Lakewood-Amedex Biotherapeutics Inc. Common Stock from 2023 to 2025, covering 3 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market value of Lakewood-Amedex Biotherapeutics Inc. Com.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -407.9% | $-1.96 Million | $481.60K | $2.45 Million | ▼ -446.2 pp |
| 2024 | 38.3% | $409.61K | $1.07 Million | $660.97K | ▼ -27.9 pp |
| 2023 | 66.1% | $4.56 Million | $6.89 Million | $2.34 Million | — |